Sierra Oncology, Inc. (NASDAQ:SRRA) shares crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $15.37 and traded as high as $16.11. Sierra Oncology shares last traded at $15.90, with a volume of 4,456 shares trading hands.
A number of research analysts have recently commented on SRRA shares. Lifesci Capital restated an “outperform” rating on shares of Sierra Oncology in a report on Friday, November 6th. Oppenheimer restated a “buy” rating and issued a $27.00 target price on shares of Sierra Oncology in a research note on Tuesday, November 10th. ValuEngine raised shares of Sierra Oncology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 5th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Sierra Oncology in a report on Friday, December 11th. Finally, Zacks Investment Research upgraded Sierra Oncology from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Saturday, December 19th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $24.67.
The stock has a market cap of $175.55 million, a PE ratio of -0.82 and a beta of 1.34. The business has a 50 day moving average price of $15.37 and a 200 day moving average price of $13.09.
Several hedge funds have recently bought and sold shares of the company. Boothbay Fund Management LLC acquired a new stake in shares of Sierra Oncology in the third quarter valued at approximately $405,000. Morgan Stanley grew its position in Sierra Oncology by 2,626.1% in the third quarter. Morgan Stanley now owns 10,250 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 9,874 shares during the period. Vivo Capital LLC acquired a new stake in Sierra Oncology during the third quarter worth $20,455,000. WINTON GROUP Ltd purchased a new stake in Sierra Oncology in the third quarter valued at $111,000. Finally, Bridgeway Capital Management Inc. acquired a new position in shares of Sierra Oncology in the 2nd quarter valued at $425,000. Institutional investors and hedge funds own 65.21% of the company’s stock.
About Sierra Oncology (NASDAQ:SRRA)
Sierra Oncology, Inc researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis.
Featured Story: What are the qualifications of a portfolio manager?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.